LncRNA HAND2‐AS1 represses cervical cancer progression by interaction with transcription factor E2F4 at the promoter of C16orf74

Gong, Junling; Fan, Haiying; Deng, Jing; Zhang, Qiu-Mei

doi:10.1111/jcmm.15117

Cited by 40 publications

(23 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,13,14 Interleukin 6 (IL-6) is a proin ammatory cytokine, which is upregulated frequently in OA patients and osteoarthritis animal models. 15,16,17,18 HAND2-AS1 is a newly de ned lncRNA and has been proved play an important role in different types of tumors, such as prostate cancer, 19 ovarian carcinoma, 20 cervical cancer, 21 intraductal papillary mucinous neoplasm, 22 colorectal cancer, 23 liver cancer 24 and liver cancer stem cell. 25 However, the biological role and clinical function of HAND2-AS1 in OA are unclear.…”

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: lncRNA HAND2-AS1 is Down Regulated in Osteoarthritis and Regulates IL‐6 Expression in Chondrocyte

Zhou

Shen³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Osteoarthritis (OA) is a leading cause of disability. The incidence of OA is progressively rising due to the diminishing levels of physical activity and ever-expanding ageing population. However, the mainstay for OA treatment only can improve symptoms without delay the progression of this severe disease. This study aimed to explore the biological role and clinical function of lncRNA HAND2-AS1 in OA.Methods: Blood samples and synovial fluid were collected from OA patients and normal subjects. HAND2-AS1 expression was detected by qRT-PCR and IL-6 expression was detected by ELISA; The plasma levels of HAND2-AS1 were also detected in different ages, stages and gender of OA patients and controls. Furthermore, the ROC curve was used to analyze whether HAND2-AS1 can distinguish OA patients from normal subjects. Also, Pearson correlation coefficient analysis was used to analyze the correlation between lncRNA HAND2-AS1 and IL-6. In addition, western blot was used to detect the IL-6 level upon HAND2-AS1 overexpression in chondrocytes and qRT-PCR was used to detect the HAND2-AS1 level after endogenous IL-6 treatment. Results: HAND2-AS1 and IL-6 were dysregulated in plasma and synovial fluid of OA patients. The expression of HAND2-AS1 in plasma of OA patients was decreased with aging and progression. Furthermore, HAND2-AS1 downregulation effectively distinguished OA patients from the healthy controls. Overexpression of HAND2-AS1 inhibited IL‐6 expression in chondrocytes, while treatment with exogenous IL‐6 did not affect HAND2-AS1 expression. Conclusion: HAND2-AS1 effectively distinguished OA patients from the healthy controls and regulates IL‐6 expression in human chondrocytes. Abbreviations: Long non-coding RNA, lncRNA; Osteoarthritis, OA; Interleukin 6, IL‐6; Negative control plasmid, NC; Real‐time quantitative polymerase chain reaction, qRT-PCR; Enzyme‐linked immunosorbent assay, ELISA; Receiver operating characteristic curve, ROC; Trial registration: ChiCTR, ChiCTR2000038635. Registered 11 February 2019, http:// http://www.chictr.org.cn/ ChiCTR2000038635

show abstract

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: lncRNA HAND2-AS1 is Down Regulated in Osteoarthritis and Regulates IL‐6 Expression in Chondrocyte

Zhou

Shen³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Interleukin 6 (IL-6) is a proinflammatory cytokine, which is upregulated frequently in OA patients and osteoarthritis animal models [ 15 – 18 ]. HAND2-AS1 is a newly defined long non-coding RNA (lncRNA) and has been proved play an important role in different types of tumors, such as prostate cancer [ 19 ], ovarian carcinoma [ 20 ], cervical cancer [ 21 ], intraductal papillary mucinous neoplasm [ 22 ], colorectal cancer [ 23 ], liver cancer [ 24 ], and liver cancer stem cell [ 25 ]. However, the biological role and clinical function of HAND2-AS1 in OA and the relationship between HAND2-AS1 and IL-6 are unclear.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: lncRNA HAND2-AS1 is downregulated in osteoarthritis and regulates IL-6 expression in chondrocytes

Zhou

Shen

et al. 2021

J Orthop Surg Res

View full text Add to dashboard Cite

Background Osteoarthritis (OA) is a leading cause of disability. The incidence of OA is progressively rising due to the diminishing levels of physical activity and ever-expanding aging population. However, the mainstay for OA treatment only can improve symptoms without delay the progression of this severe disease. This study aimed to explore the biological role and clinical function of lncRNA HAND2-AS1 in OA. Methods Blood samples and synovial fluid were collected from OA patients and normal subjects. HAND2-AS1 expression was detected by qRT-PCR and IL-6 expression was detected by ELISA. The plasma levels of HAND2-AS1 were also detected in different ages, stages, and gender of OA patients and controls. Furthermore, the ROC curve was used to analyze whether HAND2-AS1 can distinguish OA patients from normal subjects. Also, Pearson correlation coefficient analysis was used to analyze the correlation between lncRNA HAND2-AS1 and IL-6. In addition, Western blot was used to detect the IL-6 level upon HAND2-AS1 over-expression in chondrocytes and qRT-PCR was used to detect the HAND2-AS1 level after endogenous IL-6 treatment. Results HAND2-AS1 and IL-6 were dysregulated in plasma and synovial fluid of OA patients. The expression of HAND2-AS1 in plasma of OA patients was decreased with aging and progression. Furthermore, HAND2-AS1 downregulation effectively distinguished OA patients from the healthy controls. Over-expression of HAND2-AS1 inhibited IL-6 expression in chondrocytes, while treatment with exogenous IL-6 did not affect HAND2-AS1 expression. Conclusion HAND2-AS1 effectively distinguished OA patients from the healthy controls and regulates IL-6 expression in human chondrocytes. Trial registration ChiCTR, ChiCTR2000038635. Registered 11 February 2019

show abstract

“…The kelch-like family member 15 (KLHL15) can encode a member of the kelch-like family of proteins and is involved in protein ubiquitination and cytoskeletal organization (Ferretti et al, 2016;Zhou et al, 2019), but few studies focus on cancers. E2F transcription factor 4 (E2F4), a member of the E2F family of transcription factors, plays an important role in inhibiting proliferation-associated genes, and its gene mutation and increased expression are related to different cancers (Gong et al, 2020;Zhuang et al, 2020). In the future, these genes should be deeply investigated roles in SCC.…”

Section: Discussionmentioning

confidence: 99%

A Novel Signature for Predicting Prognosis of Smoking-Related Squamous Cell Carcinoma

Chen

Cheng

Li³

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Tobacco smoking is an established risk factor for squamous cell carcinoma (SCC). We obtained smoking-related SCC, including cervical SCC (CSCC), esophageal SCC (ESCC), head and neck SCC (HNSC), and lung SCC (LUSC), from The Cancer Genome Atlas (TCGA) database to investigate the association between smoking status (reformed and current smoking) and prognosis. We found that reformed smokers had a better prognosis than current smokers in CSCC (p = 0.003), HNSC (p = 0.019), and LUSC (p < 0.01) cohorts. Then, we selected LUSC cohorts as the training cohort and other SCC cohorts as the test cohorts. Function analysis revealed that homologous recombination (HR) was the most significant pathway involved in smoking-induced LUSC. Moreover, the effect of cross-talk between the smoking status and HR deficiency (HRD) on the prognosis was further evaluated, revealing that quitting smoking with high HRD scores could significantly improve patients’ prognosis (p < 0.01). To improve prognosis prediction and more effectively screen suitable populations for platinum drugs and poly-ADP-ribose polymerase (PARP) inhibitors, we constructed a risk score model using smoking- and HRD-related genes in LUSC. The risk score model had high power for predicting 2-, 3-, and 5-year survival (p < 0.01, AUC = 0.67, 0.66, and 0.66). In addition, the risk scores were an independent risk factor for LUSC (HR = 2.34, 95%CI = 1.70–3.23). The practical nomogram was also built using the risk score, smoking status, and other clinical information with a good c-index (0.72, 95%CI = 0.70–0.74). Finally, we used other TCGA SCC cohorts to confirm the reliability and validity of the risk score model (p < 0.01 and AUC > 0.6 at 2, 3, and 5 years in CSCC and HNSC cohorts). In conclusion, the present study suggested that smoking cessation should be a part of smoking-related SCC treatment, and also provided a risk score model to predict prognosis and improve the effectiveness of screening the platinum/PARP population.

show abstract

LncRNA HAND2‐AS1 represses cervical cancer progression by interaction with transcription factor E2F4 at the promoter of C16orf74

Cited by 40 publications

References 34 publications

WITHDRAWN: lncRNA HAND2-AS1 is Down Regulated in Osteoarthritis and Regulates IL‐6 Expression in Chondrocyte

WITHDRAWN: lncRNA HAND2-AS1 is Down Regulated in Osteoarthritis and Regulates IL‐6 Expression in Chondrocyte

RETRACTED ARTICLE: lncRNA HAND2-AS1 is downregulated in osteoarthritis and regulates IL-6 expression in chondrocytes

A Novel Signature for Predicting Prognosis of Smoking-Related Squamous Cell Carcinoma

Contact Info

Product

Resources

About